2023 Duke-ISCVID Criteria for Infective Endocarditis
Updated 2023 Duke-ISCVID criteria for diagnosis of infective endocarditis (IE), replacing the original 2000 Duke criteria. Incorporates PET/CT and new pathogen definitions.
Score interpretation
→ Definite IE by pathological criteria: Histological/microbiological confirmation from surgery or autopsy. Ensure full antibiotic course; surgical findings guide management.
→ Definite IE (clinical): 2 major, 1 major + 3 minor, or 5 minor criteria. Full 4–6 week IV antibiotic therapy guided by microbiology. Cardiology + ID team involvement. Assess for surgical indications.
→ Possible IE: 1 major + 1 minor, or 3 minor criteria. Initiate empirical antibiotic therapy; repeat blood cultures; echocardiogram (TOE if TTE inadequate); cardiac surgery input.
→ IE unlikely (rejected): Criteria not met. Consider alternative diagnosis. If high clinical suspicion persists, repeat cultures and imaging; re-evaluate after 5–7 days.
Interpretation bands for the Duke-ISCVID 2023. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Featured in these MRCEM clinical pathways
The Duke-ISCVID 2023 is covered in detail — with RCEM/NICE evidence base, indications and pitfalls — in the following exam-focused pathways on our sister siteReviseMRCEM.
MRCEM Primary / Intermediate / OSCE candidates: each pathway includes exam-style questions, RCEM/NICE citations, and FAQ summaries.
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.